Drug Repurposing for the Treatment of Acute Myeloid Leukemia
Open Access
- 29 November 2017
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 4, 211
Abstract
Acute myeloid leukemia (AML) is a heterogeneous disease characterized by the accumulation of immature myeloid progenitor cells in the bone marrow, compromising normal blood cell production and ultimately resulting in bone marrow failure. With overall five years survival at 20% in all patients and 50% in the 18-65 years age group, new medicines are needed, and it is proposed that development of repurposed drugs may be a part of the new therapy needed. AML is subdivided into recurrent molecular entities based on molecular genetics increasingly accessible for precision medicine. Novel therapy developments form a basis for novel multimodality therapy, and includes liposomal daunorubicin/cytarabine, broad or FLT3 specific tyrosine kinase inhibitors, Bcl-2 family inhibitors, selective inhibitors of nuclear export, metabolic inhibitors and demethylating agents. Immunotherapy is in early development in AML with the exceptional re-approval of a toxin-conjugated anti-CD33. However, the full potential of small molecule inhibitors and modalities like immunological checkpoint inhibitors, immunostimulatory small molecules and CAR-T cell therapy is unknown. Some novel therapeutics will certainly benefit AML patient subgroups, however; due to high cost more affordable alternatives are needed globally. Also the heterogeneity of AML will likely demand a broader repertoire of therapeutic molecules. Drug repurposing or repositioning represent a source for potential therapeutics with well-known toxicity profile and reasonable pricing. This implies that biomarkers of response need to be accompanying development of anti-leukemic therapies for sharply defined patient subgroups. We will illustrate repurposing in AML with selected examples, and discuss some experimental and regulatory limitations that may obstruct this development.Keywords
Funding Information
- Kreftforeningen (144345, 421828 71309 - PR-2006-0334)
This publication has 119 references indexed in Scilit:
- Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancerJournal of Cancer Research and Clinical Oncology, 2013
- Acute promyelocytic leukemia, arsenic, and PML bodiesJournal of Cell Biology, 2012
- New sources of drugs for hematologic malignanciesBlood, 2011
- Phase 1 study of arsenic trioxide, high‐dose cytarabine, and idarubicin to down‐regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemiaCancer, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Specific cellular signal-transduction responses to in vivo combination therapy with ATRA, valproic acid and theophylline in acute myeloid leukemiaBlood Cancer Journal, 2011
- Molecular and Therapeutic Potential and Toxicity of Valproic AcidJournal of Biomedicine and Biotechnology, 2010
- The risks and benefits of long‐term use of hydroxyurea in sickle cell anemia: A 17.5 year follow‐upAmerican Journal of Hematology, 2010
- Structural and Functional Alterations of FLT3 in Acute Myeloid LeukemiaClinical Cancer Research, 2009
- Evolving anticancer drug valproic acid: Insights into the mechanism and clinical studiesMedicinal Research Reviews, 2005